Functional characterization of a PROTAC directed against BRAF mutant V600E

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The RAS-ERK pathway, involving RAF kinases, regulates cell growth and is frequently mutated in cancers.
• Mutations in BRAF, particularly BRAF V600E, are key drivers of various human cancers.
• Conventional BRAF inhibitors face limitations due to resistance mechanisms, often involving RAF kinase dimerization.

Purpose of the Study:

• To investigate the efficacy of a proteolysis-targeting chimera (PROTAC) approach for inhibiting oncogenic BRAF.
• To develop a novel therapeutic strategy that overcomes resistance to existing BRAF inhibitors.

Main Methods:

• Design and synthesis of a BRAF-targeting PROTAC (P4B).
• Evaluation of P4B's specificity and inhibitory activity in BRAF V600E cancer cell lines.
• Assessment of P4B's efficacy in cell lines with BRAF mutations conferring resistance to conventional inhibitors.

Main Results:

• The PROTAC P4B demonstrated superior specificity and inhibitory effects compared to non-PROTAC controls.
• P4B effectively inhibited BRAF in cell lines harboring resistance-conferring BRAF mutations.
• This study provides proof of concept for PROTACs as an alternative to conventional chemical inhibition for oncogenic BRAF.

Conclusions:

• Proteolysis-targeting chimeras represent a promising alternative therapeutic modality for targeting oncogenic BRAF.
• PROTACs can overcome resistance mechanisms associated with conventional BRAF inhibitors.
• This approach offers a potential new avenue for treating cancers driven by BRAF mutations.